Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
filingDate |
2019-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ff4175b36fbbac763c9af205c6f1ea1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4259d96e79a95b15feced7ccadf9983b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df90db992b91a59c7277f769db7e6b1e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb3765d185e9e337d155627ad1d1b612 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_695d3f54e2993662e9f78872976ee471 |
publicationDate |
2019-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2019233921-A1 |
titleOfInvention |
Oligonucleotides for modulating atxn2 expression |
abstract |
The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022517475-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7288052-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11066669-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11286485-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020201339-A1 |
priorityDate |
2018-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |